Ridge Diagnostics is a neurodiagnostic company that offers a groundbreaking blood test for Major Depressive Disorder (MDD). With their CLIA certified laboratory in North Carolina, they provide the first-in-class blood test that utilizes their proprietary Human Biomarker Library and Biomarker Hyper-Map™ technology platform. This innovative approach allows them to develop multi-variant biological marker assays and diagnostic algorithms for the diagnosis, selection, and monitoring of MDD and other neuropsychiatric disorders.

This blood test for depression is a game-changer in the psychiatric industry as it provides objective test information, enabling physicians to accurately diagnose MDD, choose appropriate treatments, and effectively manage their patients. This is a significant advancement compared to the current practice of relying on clinical questions and assessments, which can be challenging for patients to validate their disorder. With over 19 million adults affected by depression in the US annually, Ridge Diagnostics' blood test offers hope for better patient care and treatment.

Their commitment to utilizing blockchain technology to securely store patient data further highlights their dedication to enhancing the field of psychiatry. Ridge Diagnostics is making a meaningful impact by revolutionizing how depression is diagnosed and managed